Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001577123 | SCV001804454 | uncertain significance | not provided | 2021-04-01 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV002493488 | SCV002779991 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 12; Usher syndrome type 1D; Pituitary adenoma 5, multiple types | 2021-07-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001577123 | SCV003522559 | likely benign | not provided | 2024-11-29 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004035482 | SCV004922012 | uncertain significance | Inborn genetic diseases | 2023-10-05 | criteria provided, single submitter | clinical testing | The c.8344G>A (p.D2782N) alteration is located in exon 59 (coding exon 58) of the CDH23 gene. This alteration results from a G to A substitution at nucleotide position 8344, causing the aspartic acid (D) at amino acid position 2782 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001279072 | SCV001466133 | uncertain significance | Usher syndrome type 1 | 2020-04-17 | no assertion criteria provided | clinical testing |